Sangamo Therapeutics Inc has announced plans to acquire TxCell SA in a deal that will give it ownership of the French company’s regulatory T cell technology for the development of therapies against autoimmune diseases. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
